Comparison of efficacy of commercial one dose and two dose PCV2 vaccines using a mixed PRRSV–PCV2–SIV clinical infection model 2–3-months post vaccination

Department of Veterinary Diagnostic and Production Animal Medicine, College of Veterinary Medicine, Iowa State University, Ames, IA 50011, United States.
Vaccine (Impact Factor: 3.49). 02/2009; 27(7):1002-7. DOI: 10.1016/j.vaccine.2008.11.105
Source: PubMed

ABSTRACT The study objectives were to compare the duration of immunity of commercially available, one and two dose, killed porcine circovirus type 2 (PCV2) vaccines. Sixty, 3.5-week-old pigs were randomly divided into six treatment groups: one dose vaccines (FDAH-1, BIVI-1), two dose vaccines (Intervet-2, FDAH-2), and non-vaccinated negative and positive controls. Tissue homogenate challenge was conducted 63 (two doses) or 84 (one dose) days post vaccination. Viremia was reduced by 78.5% in pigs vaccinated with one dose and by 97.1% in pigs vaccinated with two dose products and overall microscopic lymphoid lesions were reduced by 78.7% and 81.8%, respectively.

1 Follower
  • [Show abstract] [Hide abstract]
    ABSTRACT: The aim of this research was to determine the effect of vaccination on the amount of antibody titers specific for PCV2, and to determine the effect of vaccination on characteristics of pig production. The first group (A) was vaccinated at 15 days old, the second (B) at 21 days old while the third (C) was the control group. Group B piglets attained the best results, so the vaccination of piglets at 21 days old would have an advantage compared to vaccination at 15 days old, although we note that at 15 days old, there is a far greater influence of maternal antibodies on the creation and development of immune responses in the piglets after vaccination.
    Kafkas Üniversitesi Veteriner Fakültesi Dergisi 05/2014; 20(3). DOI:10.9775/kvfd.2013.10373 · 0.29 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Porcine circovirus type 2 (PCV2) causes porcine circovirus-associated disease. Capsid (Cap) protein of PCV2 is the principal immunogenic protein that induces neutralizing antibodies and protective immunity. GM-CSF is an immune adjuvant that enhances responses to vaccines. In this study, recombinant baculoviruses Ac-Cap and Ac-Cap-GM-CSF expressing the Cap protein alone and co-expressing the Cap protein and porcine GM-CSF, respectively, were constructed successfully. The target proteins were analyzed by western blotting and IFA. Further, these proteins were confirmed by electron microscopy, which showed that Cap proteins could self-assemble into virus-like particles having diameters of 17-25nm. Animal experiments showed that pigs immunized with Cap-GM-CSF subunit vaccine showed significantly higher levels of PCV2-specific antibodies and neutralizing antibodies than pigs immunized with the Cap subunit vaccine and a commercial vaccine (Ingelvac CircoFLEX; P<0.05). After PCV2 wild strain challenged, Pigs receiving the Cap-GM-CSF subunit vaccine showed significantly higher average daily weight gain after wild-type PCV2 challenge than pigs receiving the other three vaccines (P<0.05). None of PCV2 DNA was detected in all immunized animals, except control animals immunized with phosphate-buffered saline. These results indicated that GM-CSF was a powerful immunoadjuvant for PCV2 subunit vaccines because it enhanced humoral immune response and improved immune protection against PCV2 infection in pigs. Thus, the novel Cap-GM-CSF subunit vaccine has the potential to be used as an effective and safe vaccine candidate against PCV2 infection. Copyright © 2015. Published by Elsevier Ltd.
    Vaccine 04/2015; 33(21). DOI:10.1016/j.vaccine.2015.03.090 · 3.49 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Porcine circovirus type 2 (PCV2)-systemic disease (SD) (initially named as postweaning multisystemic wasting syndrome) was discovered as an occasional disease affecting postweaning pigs in North-America by mid-1990s. Soon afterward, it was noticed as a devastating disease worldwide. Such scenario prompted to develop vaccine prototypes that worked fairly well under experimental conditions. In spite of the multifactorial nature of the PCV2-SD, the first commercialized vaccines containing inactivated or chimeric PCV2 viruses or PCV2 Cap protein represented by far the best system to control the disease under farm conditions. Moreover, vaccination of non-clinically affected pigs demonstrated a significant improvement of average daily weight gain and, in consequence, the economic importance of the PCV2-subclinical infection. In the present review, a comprehensive overview on PCV2 vaccines and best practices on PCV2 vaccination strategies are presented and discussed.
    Expert Review of Vaccines 11/2014; 14(3). DOI:10.1586/14760584.2015.983084 · 4.22 Impact Factor